Chandler Capital

Chandler Capital

Expertise: Technology, Pharmaceutical, Energy, GARP

Chandler Capital is the work of Ian Hartana and Vayun Chugh.

Ian Hartana is a self-taught investor whose work has been featured on Seeking Alpha under the organization AlmaStreet Capital. Being on the student advisory board of the Young Investors Society, he is a long-time advocate for the advancement of financial literacy and has competed on the international level in multiple competitions. In his free time, he enjoys exploring the intersection between behavioral science and economics through writing on the platform Medium and is currently working as an intern at a small venture capital firm.

Vayun Chugh is also a self-taught investor and is both an editor and writer for AlmaStreet Capital. He is the president of his school’s finance club alongside Ian Hartana, and has also competed in multiple international competitions. Through his ongoing research in the medical field, Vayun has developed a deep understanding of the pharmaceutical industry and knows the characteristics of an undervalued company.

Ian and Vayun’s expertise lies in finding value in undervalued companies in the tech, pharmaceutical, and energy sectors which have the potential for growth at a reasonable price. They have a long-term investment horizon and consider ESG as an increasingly important factor in their research process.

Recent Articles

Prepare for a Charge: 3 Battery Stocks to Buy Before an EV Rebound

While the sector is in a lull, load up on these three battery stocks for when EV demand rebounds in the future.

Wall Street Favorites: 3 Space Stocks With Strong Buy Ratings for April 2024

The unknown of space is so appealing to investors. The sky is the limit when it comes to investing in Wall Street’s strong buy space stocks. 

3 Retail Stocks to Buy Now: Q2 Edition

Retail companies are often the bellwether for a strengthening economy and consumer sentiment. Here are three picks to get exposure into Q2!

3 Energy Stocks to Buy Now: Q2 Edition

From EV catalysts to geopolitical tensions, these three energy stocks to buy now are staying a cut ahead of the headwinds into Q2.

Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.